One of the most important psychedelic drug discovery companies in the world is starting to prepare for how psychedelic assisted therapies will actually reach patients in a clinical setting.

‍What’s happening:‍

  • Psychedelic biotechnology company COMPASS Pathways (NASDAQ: CMPS) has entered into a new multi year research collaboration with Greenbrook TMS (NASDAQ: GNBH)
  • The focus of the partnership between COMPASS and Greenbrook will be exploring potential ways to integrate psychedelic assisted therapies in a clinical setting and ensure the best patient outcomes possible

Why it matters:‍

  • COMPASS Pathway’s lead drug candidate COMP360 is a synthetic psilocybin compound meant to be administered with the guidance of a therapist
  • Greenbrook has an extensive clinical network across the United States, with many of their existing patients being a potential future fit for COMP360
  • Beginning to build data based frameworks for how psychedelic assisted therapies will actually be administered is a critical step forward for psychedelic therapeutics integrating into existing healthcare infrastructure

Going deeper:‍

  • COMP360 is currently in a Phase III trial for Treatment Resistant Depression after overwhelmingly positive results from their Phase I and Phase II trials
  • The FDA has already designated COMP360 as a “Breakthrough Therapy” for Treatment Resistant Depression
  • Upon completion of the Phase III clinical trial, COMPASS Pathways intends to seek FDA approval for being able to administer COMP360 in clinics across the United States

By the numbers:‍

  • In the successful Phase II clinical trial for COMP360, patients who received a single 25mg dose of COMP360 saw significant improvements in their symptoms within just 3 weeks